FRONTIERS IN ENDOSCOPY, SERIES #31Endoscopic Management of Barretts Esophagus: An Update on Radiofrequency Ablation
Barrett's esophagus (BE) is a precancerous state with a field defect, and is the first step in the metaplasia-dysplasia-cancer sequence, in which molecular aberrations precede neoplasia; Radiofrequency ablation (RFA) can eliminate such mutations. A wait and watch policy might be inadequate to reliably detect early changes. Here we discuss BE risk factors, diagnosis and management, and present an update on the use of RFA in the management of BE.
NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #157Achalasia And Nutrition: Is it Simple Physics or Biology?
Achalasia is one of the most studied motility disorders of the esophagus and delay in diagnosis can result in significant patient morbidity and impaired quality of life. Esophagogastroduodenoscopy is necessary to rule out potential malignancy that can mimic achalasia. Although there are no curative therapies currently, excellent palliation of symptoms can be achieved in <90% of patients with the use of graded pneumatic dilatation, surgical myotomy or per-oral endoscopic myotomy. This article briefly discusses the clinical presentation, diagnosis, and management options in patients with achalasia followed by insights into nutritional implications that are often neglected.
GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #20Current Treatment Strategies for Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) affects 11% of the worldÂs population. The pathophysiology of IBS is not well understood but new concepts are emerging. In this article, we provide an update on IBS therapies newly approved by the Food and Drug Administration (FDA), suggest strategies for incorporating the spectrum of the medications that are already being utilized for specific IBS patient settings and preview new therapeutic directions.
COLORECTAL CANCER: REAL PROGRESS IN DIAGNOSIS AND TREATMENT, SERIES #8Quality in Colonoscopy
The use of screening colonoscopy to identify early cancer and remove pre-malignant polyps has become the keystone in reducing deaths from colon cancer. A population-based screening test must be effective, safe, cost-efficient and widely available; colonoscopy, on the contrary, is invasive, expensive and potentially dangerous. In this review, we discuss important quality indicators suggested by professional societies, which help in optimizing general performance of colonoscopy. These indicators are process indicators as opposed to true outcome measures. We will present scientific evidence supporting the utility of these measures, possible interventions to improve these measures as well as potential caveats that still need to be addressed.
A CASE REPORTSymptomatic Pancreatic Insulinoma Successfully Treated with Alcohol Ablation
Outpatient Nutrition Care and Home Nutrition Support
This book was written by multiple registered dieticians throughout the United States, with the purpose of providing nutritional care information for health care providers in the outpatient setting. It has a total of 14 chapters which are grouped into 3 sections: Outpatient Nutrition Care, Home Nutrition Support and Summary.
Advanced Pancreaticobiliary Endoscopy
This book entitled Advanced Pancreaticobiliary Endoscopy provides a very thorough yet succinct insight into the concepts of advanced pancreatobiliary endoscopy. The book is well organized and addresses all aspects of the scope and practice of endoscopic retrograde cholangiopancreatography (ERCP) as well as role of endoscopic ultrasound (EUS) for pancreatobiliary indications. The evidence based approach to each concept along with the corollary videos for each chapter provide an excellent resource for those learning pancreatobiliary endoscopy.
EXACT SCIENCES ANNOUNCES INCLUSION OF COLOGUARD®® IN HEDIS QUALITY MEASURES
MADISON, WI - Exact Sciences Corp. (Nasdaq: EXAS) announced that Cologuard® is now included in the 2017 Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for colorectal cancer screening. The new quality measures were published by the National Committee for Quality Assurance (NCQA). More than 90 percent of America's health plans measure quality based on HEDIS.
SYNERGY PHARMACEUTICALS PRESENTS LONG-TERM DATA FOR PLECANATIDE IN CHRONIC IDIOPATHIC CONSTIPATION AT THE AMERICAN COLLEGE OF GASTROENTEROLOGY (ACG) ANNUAL SCIENTIFIC MEETING
NEW YORK - Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) presented new long-term safety data of plecanatide, its investigational, orally-administered compound currently being evaluated by the U.S. Food and Drug Administration (FDA) for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). These data, which were presented at the American College of Gastroenterology (ACG) annual scientific meeting, showed that plecanatide was associated with low adverse events and low discontinuation rates in patients with CIC who received plecanatide (3 mg or 6 mg) once-daily for up to 72 weeks.
ALLERGAN PARTNERS WITH SONARMD® TO DEVELOP INNOVATIVE IBS-D PATIENT ENGAGEMENT PLATFORM FOR BETTER IDENTIFICATION AND CARE OF IBS-D PATIENTS
DUBLIN - Allergan plc (NYSE: AGN) announced a collaboration with SonarMD®, a leader in population health management, on the development of clinical decision support (CDS) and patient engagement tools which can be used to facilitate physician identification of patients suffering from Irritable Bowel Syndrome with Diarrhea (IBS-D) in clinical practice and monitor their treatment outcomes. Moreover, the companies will establish a patient engagement platform which can be used to evaluate symptoms and health outcomes among patients with IBS-D in a real-world clinical setting.